Advanced Proteome Therapeutics Stock Net Income
| APTCFDelisted Stock | USD 0.0002 0.00 0.00% |
Advanced Proteome technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Advanced Proteome's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Advanced Proteome's valuation are provided below:Advanced Proteome Therapeutics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Advanced |
Search Suggestions
| A | Agilent Technologies | Company |
| A | Vaulta | Cryptocurrency |
| AFGD | American Financial Group | Company |
| ACP | Aberdeen Income Credit | Fund |
| AK | AK | ETF |
| AMZ | Alerian MLP Index | Index |
| A08163AA4 | USA08163AA41 | Corporate Bond |
| ALIUSD | Aluminum Futures | Commodity |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Advanced Proteome Therapeutics reported net income of 759.62 K. This is 99.78% lower than that of the Biotechnology sector and 98.92% lower than that of the Health Care industry. The net income for all United States stocks is 99.87% higher than that of the company.
Advanced Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Advanced Proteome's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Advanced Proteome could also be used in its relative valuation, which is a method of valuing Advanced Proteome by comparing valuation metrics of similar companies.Advanced Proteome is currently under evaluation in net income category among its peers.
Advanced Fundamentals
| Return On Asset | -1.07 | |||
| Current Valuation | 660.53 K | |||
| Shares Outstanding | 41.13 M | |||
| Shares Owned By Insiders | 10.53 % | |||
| Price To Earning | 2.98 X | |||
| Price To Book | 4.92 X | |||
| Gross Profit | (1.71 K) | |||
| EBITDA | 631.22 K | |||
| Net Income | 759.62 K | |||
| Cash And Equivalents | 761.6 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 227.41 K | |||
| Debt To Equity | 4.65 % | |||
| Current Ratio | 0.55 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (693.58 K) | |||
| Earnings Per Share | 0.02 X | |||
| Number Of Employees | 11 | |||
| Beta | 1.55 | |||
| Market Capitalization | 2.47 M | |||
| Total Asset | 636.41 K | |||
| Z Score | 6.0 | |||
| Net Asset | 636.41 K |
About Advanced Proteome Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Advanced Proteome Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Advanced Proteome using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Advanced Proteome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Advanced Pink Sheet
If you are still planning to invest in Advanced Proteome check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Advanced Proteome's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |